MedTrace Logo

Oral Bioavailability of Two Melatonin Supplements

NCT05835258 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2023-08-01

No results posted yet for this study

Summary

Results from several clinical studies show that orally administered melatonin has low bioavailability and a very short half-life. Phenyl capsaicin, a synthetic analogue of capsaicin, might increase its bioavailability by inhibiting the enzymes involved in its hepatic metabolism.

Thus, the hypothesis of the present study is that the administration of melatonin supplement with phenyl capsaicin presents greater bioavailability than a melatonin supplement that does not contain phenyl capsaicin.

Conditions

  • Bioavailability

Interventions

DIETARY_SUPPLEMENT

Melatonin with phenyl capsaicin

Blood samples will be collected at different time points following the oral administration of the melatonin supplement with phenyl capsaicin

DIETARY_SUPPLEMENT

Melatonin without phenyl capsaicin

Blood samples will be collected at different time points following the oral administration of the melatonin supplement without phenyl capsaicin

Sponsors & Collaborators

  • URIACH, S.L.

    collaborator UNKNOWN

  • Fundació Eurecat

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-05-30
Primary Completion
2023-07-14
Completion
2023-07-14

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05835258 on ClinicalTrials.gov